Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


09.05.2022

4 Aliment Pharmacol Ther
1 BMC Gastroenterol
5 Dig Dis Sci
2 Dis Colon Rectum
1 Gastroenterology
1 Hum Pathol
4 Inflamm Bowel Dis
3 J Crohns Colitis
1 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
    Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
    PubMed         Abstract available

  2. MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
    Systematic review-Pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
    PubMed         Abstract available

  3. KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1348-1349.
    PubMed        

  4. LOVATT J, Selinger CP
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
    Aliment Pharmacol Ther. 2022;55:1346-1347.
    PubMed        


    BMC Gastroenterol

  5. JIANG J, Chen L, Chen Y, Chen H, et al
    Exclusive enteral nutrition remodels the intestinal flora in patients with active Crohn's disease.
    BMC Gastroenterol. 2022;22:212.
    PubMed         Abstract available


    Dig Dis Sci

  6. BUERKLE KS, Vernon-Roberts A, Ho C, Schultz M, et al
    A Short Knowledge Assessment Tool Is Valid and Acceptable for Adults with Inflammatory Bowel Disease.
    Dig Dis Sci. 2022 May 5. pii: 10.1007/s10620-022-07507.
    PubMed         Abstract available

  7. HILL E, Nguyen NH, Qian AS, Patel S, et al
    Impact of Comorbid Psychiatric Disorders on Healthcare Utilization in Patients with Inflammatory Bowel Disease: A Nationally Representative Cohort Study.
    Dig Dis Sci. 2022 May 3. pii: 10.1007/s10620-022-07505.
    PubMed         Abstract available

  8. CON D, Vasudevan A
    Real-World Guidance from Artificial Intelligence? Predicting Outcomes of Inflammatory Bowel Disease Using Machine Learning.
    Dig Dis Sci. 2022 May 3. pii: 10.1007/s10620-022-07511.
    PubMed        

  9. BRENNER EJ, Long MD, Kappelman MD, Zhang X, et al
    Development of an Inflammatory Bowel Disease-Specific Medication Adherence Instrument and Reasons for Non-adherence.
    Dig Dis Sci. 2022 May 3. pii: 10.1007/s10620-022-07517.
    PubMed         Abstract available

  10. WANG G, Karimi N, Willmann L, Pipicella J, et al
    A Novel Decision Aid Improves Quality of Reproductive Decision-Making and Pregnancy Knowledge for Women with Inflammatory Bowel Disease.
    Dig Dis Sci. 2022 Apr 30. pii: 10.1007/s10620-022-07494.
    PubMed         Abstract available


    Dis Colon Rectum

  11. HOLUBAR SD
    Expert Commentary on Chronic Perineal Sinus After Proctectomy for Crohn's Disease: Risk Reduction Strategies and Management.
    Dis Colon Rectum. 2022;65:472.
    PubMed        

  12. FUSCHILLO G, Pellino G
    Chronic Perineal Sinus After Proctectomy for Crohn's Disease: Risk Reduction Strategies and Management.
    Dis Colon Rectum. 2022;65:468-471.
    PubMed        


    Gastroenterology

  13. MA J, Wang Y, Cao H
    When neurology meets gastroenterology: an unusual case of ulcerative colitis.
    Gastroenterology. 2022 Apr 27. pii: S0016-5085(22)00447.
    PubMed        


    Hum Pathol

  14. NGUYEN J, Finkelman BS, Escobar D, Xue Y, et al
    Over-expression of Programmed Death Ligand 1 (PD-L1) in Refractory Inflammatory Bowel Disease (IBD).
    Hum Pathol. 2022 Apr 27. pii: S0046-8177(22)00101.
    PubMed         Abstract available


    Inflamm Bowel Dis

  15. DE SIRE R, Rispo A, Compare D, Tortora F, et al
    Wernicke Encephalopathy in Ulcerative Colitis.
    Inflamm Bowel Dis. 2022;28:e70-e71.
    PubMed        

  16. BATTAT R
    Authors' Reply to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease".
    Inflamm Bowel Dis. 2022;28:e61.
    PubMed        

  17. MC GETTIGAN N, Boland K, O'Toole A
    Letter to the Editor in Response to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease".
    Inflamm Bowel Dis. 2022;28:e59-e60.
    PubMed        

  18. LEBER A, Hontecillas R, Tubau-Juni N, Lichtiger S, et al
    Correction to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2022 Apr 30. pii: 6576383. doi: 10.1093.
    PubMed        


    J Crohns Colitis

  19. SHRESTHA S, Brand JS, Jaras J, Schoultz I, et al
    Association between inflammatory bowel disease and spondyloarthritis: findings from a nationwide study in Sweden.
    J Crohns Colitis. 2022 May 5. pii: 6581445. doi: 10.1093.
    PubMed         Abstract available

  20. WONG C, van Oostrom J, Bossuyt P, Pittet V, et al
    A narrative systematic review and categorisation of outcomes in Inflammatory Bowel Disease to inform a Core Outcome Set for real-world evidence.
    J Crohns Colitis. 2022 May 5. pii: 6580715. doi: 10.1093.
    PubMed         Abstract available

  21. POULLENOT F, Amiot A, Nachury M, Viennot S, et al
    Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
    J Crohns Colitis. 2022 May 5. pii: 6580681. doi: 10.1093.
    PubMed         Abstract available


    Scand J Gastroenterol

  22. MONMOUSSEAU F, Mulot L, Rusch E, Picon L, et al
    Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.
    Scand J Gastroenterol. 2022;57:566-573.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: